Health policy news
Warning that femur fractures are a class effect of bisphosphonates
Added: Tuesday 3 May 2011
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that rare atypical fractures of the femur are a class effect of bisphosphonates. The CHMP confirmed that the benefits of bisphosphonates in the treatment and prevention of bone disorders continue to outweigh their risks, but that a warning of the risk of atypical femoral fractures should be added to the prescribing information for all bisphosphonate-containing medicines in the European Union.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: